Clinical trials: Tace
Hepatocellular Carcinoma
Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. For patients with intermediate HCC (BCLC stage B), transarterial chemoembolization (TACE) has been recommended as the standard therapy in many clinical…
- Trial name
- NCT02616926
- Testing
- Hepatic resection, TACE, RFA
- Where
- 3 sites in China
- Volunteers
- 538 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Hepatocellular Carcinoma
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
The investigators are going to compare the therapeutic effect of sorafenib and transarterial chemoembolization in advanced hepatocellular carcinoma with major branch of portal vein invasion.
- Trial name
- NCT01480817
- Testing
- Sorafenib, TACE for HCC with portal vein invasion
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC
Transcatheter arterial chemoembolization (TACE) is a key palliative treatment for patients with inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT02338297
- Testing
- TACE, EGM, PVA
- Where
- 2 sites in China
- Volunteers
- 236 people
- Sponsor
- Nanjing Medical University
Hepatocellular Carcinoma
M-TACE Treatment for Unresectable Hepatocellular Carcinoma
This study aims to investigate the safety and efficacy of transarterial chenmoembolization（TACE） combined with microspheres for unresectable hepatocellular carcinoma(HCC).
- Trial name
- NCT05875558
- Testing
- M-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma Non-resectable, HCC
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
- Trial name
- IMMUWIN (NCT04522544)
- Testing
- Tremelimumab, Durvalumab, Y-90 SIRT
- Where
- 11 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Carcinoma, Hepatocellular
DCE-MRI for Assessment of Response to TACE of HCC
This study is conducted to evaluate dynamic contrast-enhanced MRI to quantify the efficacy of trans-arterial chemoembolization by comparing imaging results before and after treatment for at least one hepatic tumor and to look at…
- Trial name
- DCE-MRI (NCT02878109)
- Testing
- Post-treatment phase group, Pre-treatment phase group
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Advanced Hepatocellular Carcinoma
Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
Unlike the Asian and western regions, The vast majority of the Egyptian/Arabic Hepatocellular Carcinoma (HCC) patients are hepatitis C virus (HCV) associated.
- Trial name
- NCT01539018
- Testing
- Sorafenib, sorafenib plus tegafur-uracil
- Where
- 5 sites in Egypt
- Volunteers
- 77 people
- Sponsor
- Egyptian Society of Liver Cancer
Hepatocellular Carcinoma
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
This study was designed to evaluate the effectiveness and safety of TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT05550025
- Testing
- camrelizumab& apatinib
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Lenvatinib
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
single-center clinical trial studies have verified the safety and effectiveness of transcatheter arterial chemoembolization (TACE) combined with lenvatinib in preventing postoperative recurrence of microvascular invasion (MVI)…
- Trial name
- NCT04911959
- Testing
- Lenvatinib, TACE
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
SBRT + TACE for Primary Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility and toxicity of combining SBRT and TACE for unresectable HCC and to evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.
- Trial name
- NCT00746655
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Transcatheter Arterial Chemoembolization (TACE)
- Where
- 4 sites in United States
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
The purpose of this study is to determine that systemic chemotherapy is superior to transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02585479
- Testing
- Pirarubicin, Oxaliplatin, Lipiodol
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma Non-resectable
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
The vast majority of primary liver cancer (90%) is hepatocellular carcinoma (HCC), and the majority of HCC patients have been locally advanced or metastatic disease when they are diagnosed in clinics.
- Trial name
- PLTHCC (NCT04273100)
- Testing
- PD-1 mAb combined with TACE and lenvatinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Unresectable Hepatocellular Carcinoma
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
- Trial name
- NCT06593964
- Testing
- Thermosensitive Nanogel Embolic Agent
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above.
- Conditions
- Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
- Trial name
- NCT04834674
- Testing
- DEB-TACE combined with apatinib and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (TACE) of…
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain, Inflammation
- Trial name
- NCT06041425
- Testing
- Oxycodone, Sufentanil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC.
- Trial name
- NCT03066557
- Testing
- TACE and Apatinib, TACE
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Diffuse Large B-Cell Lymphoma, Relapsed and Refractory
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based…
- Conditions
- Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization
- Trial name
- NCT07198230
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ting YANG
Small Hepatocellular Carcinoma, Stereotactic Body Radiation Therapy
Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma participants (≤5cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators…
- Conditions
- Small Hepatocellular Carcinoma, Stereotactic Body Radiation Therapy, Transcatheter Arterial Chemoembolization
- Trial name
- NCT04161287
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Beijing 302 Hospital